Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

EVLO - Evelo Biosciences, Inc.

Previous close
0.33
0.330   100.000%

Share volume: 0
Last Updated: Mon 11 Dec 2023 09:25:22 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.25%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
6%
Profitability 0%
Dept financing 10%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
-50.00%
1 Year
-99.83%
2 Year
-100.00%
Key data
Stock price
$0.33
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.00 - $0.08
52 WEEK CHANGE
-$99.84
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
18.983 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Balkrishan Gill
Region: US
Website: evelobio.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Evelo Biosciences, Inc. discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. The company also develops EDP1815, a whole-microbe candidate for the. treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19.

Recent news